EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

Fünf-Jahres-Überlebensdaten mit Atezolizumab nach Chemotherapie bei reseziertem NSCLC Stadium IB-IIIA (IMpower010): offene randomisierte Phase-III-Studie

Enriqueta Felip iD, Nasser Altorki iD, Caicun Zhou iD, Eric Vallières, Tibor Csoszi, Ihor O Vynnychenko iD, Oleksandr Goloborodko, Achim Rittmeyer iD, Martin Reck iD, Alex Martinez-Marti iD, Hirotsugu Kenmotsu iD, Yuh-Min Chen und 10 weitere

Journal of Clinical Oncology · 20.07.2025 · 43 (21) · 2343-2349

DOI: 10.1200/jco-24-01681 ↗

Auf einen Blick

Bei reseziertem NSCLC zeigte Atezolizumab nach adjuvanter Chemotherapie in der Langzeitnachbeobachtung weiterhin Vorteile gegenüber best supportive care, besonders in PD-L1-positiven Subgruppen.

Fragestellung

Verbessert Atezolizumab nach adjuvanter Chemotherapie das krankheitsfreie Überleben und Gesamtüberleben bei reseziertem Stadium IB-IIIA NSCLC?

Methode

Offene randomisierte Phase-III-Studie; Atezolizumab 1.200 mg alle 3 Wochen für 16 Zyklen versus best supportive care nach platinbasierter Chemotherapie; Nachbeobachtung ≥5 Jahre; klinischer Cutoff 26. Januar 2024.

Ergebnisse

DFS-HR 0,85 (95 %-KI 0,71–1,01; P=.07) in der ITT-Population (n=1.005), 0,83 (95 %-KI 0,69–1,00) in Stadium II-IIIA (n=882) und 0,70 (95 %-KI 0,55–0,91) bei PD-L1 TC ≥1 % (n=476).

Schlussfolgerung der Autor:innen

IMpower010 ist die erste Studie mit Überlebensdaten nach ≥5 Jahren und zeigte weiterhin einen Nutzen von Atezolizumab gegenüber best supportive care nach adjuvanter Chemotherapie bei reseziertem Stadium II-IIIA PD-L1-selektioniertem NSCLC.

Kernaussagen

  • DFS-Vorteil besonders in PD-L1-positiven Subgruppen
  • OS-HRs: 0,97; 0,94; 0,77 in den genannten Populationen
  • Keine neuen Sicherheitssignale berichtet

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.07.2025. Verfasst von Enriqueta Felip und 21 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 6 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IMpower010 (ClinicalTrials.gov identifier: NCT02486718 ) previously showed that atezolizumab improved disease-free survival (DFS) versus best supportive care (BSC) after adjuvant chemotherapy in patients with resected non–small cell lung cancer (NSCLC). We report DFS final analysis, second overall survival (OS) interim analysis, and safety with a ≥5-year follow-up. Patients with completely resected stage IB-IIIA NSCLC were randomly assigned to atezolizumab (1,200 mg once every 3 weeks, 16 cycles) or BSC after platinum-based chemotherapy. At clinical cutoff (January 26, 2024), stratified hazard ratios (HRs; 95% CI) for DFS were 0.85 (95% CI, 0.71 to 1.01; P = .07) in the intention-to-treat (n = 1,005), 0.83 (95% CI, 0.69 to 1.00) in the all-randomized stage II-IIIA (n = 882), and 0.70 (95% CI, 0.55 to 0.91) in stage II-IIIA PD-L1 tumor cell (TC) ≥1% (n = 476) populations. Stratified HRs (95% CI) for OS were 0.97 (95% CI, 0.78 to 1.22), 0.94 (95% CI, 0.75 to 1.19), and 0.77 (95% CI, 0.56 to 1.06), respectively. The unstratified HRs (95% CI) in the stage II-IIIA PD-L1 TC ≥50% population (n = 229) were 0.48 (95% CI, 0.32 to 0.72) for DFS and 0.47 (95% CI, 0.28 to 0.77) for OS, and the unstratified HRs in the stage II-IIIA PD-L1 TC ≥50% without EGFR / ALK alterations (n = 209) population were 0.49 (95% CI, 0.32 to 0.75) and 0.44 (95% CI, 0.26 to 0.74). No new safety signals were reported. IMpower010 is the first study to report survival outcomes with a ≥5-year follow-up and continued to show benefit with atezolizumab versus BSC after adjuvant chemotherapy in patients with resected stage II-IIIA PD-L1–selected NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedNeoplasm StagingAdultChemotherapy, Adjuvant

Substanzen

atezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
  • Department of Oncology, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China.
  • Swedish Cancer Institute, Seattle, WA.
  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int, Szolnok, Hungary.
  • Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, Sumy, Ukraine.

ORCID-Profile: Enriqueta Felip, Nasser Altorki, Caicun Zhou, Ihor O Vynnychenko, Achim Rittmeyer, Martin Reck, Alex Martinez-Marti, Hirotsugu Kenmotsu, Shunichi Sugawara, Heather A Wakelee

Zitieren

APA

Felip, E., Altorki, N., Zhou, C., Vallières, E., Csoszi, T., Vynnychenko, I. O., Goloborodko, O., Rittmeyer, A., Reck, M., Martinez-Marti, A., Kenmotsu, H., Chen, Y. M., Chella, A., Sugawara, S., Fu, C., Ballinger, M., Deng, Y., Srivastava, M. K., Bennett, E., …, & IMpower010 Study Investigators (2025). Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial. Journal of Clinical Oncology, 43(21), 2343-2349. https://doi.org/10.1200/jco-24-01681

Vancouver

Felip E, Altorki N, Zhou C, Vallières E, Csoszi T, Vynnychenko IO, et al. Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial. Journal of Clinical Oncology. 2025;43(21):2343-2349. doi:10.1200/jco-24-01681

BibTeX
@article{Felip2025,
  author = {Felip, Enriqueta and Altorki, Nasser and Zhou, Caicun and Vallières, Eric and Csoszi, Tibor and Vynnychenko, Ihor O and Goloborodko, Oleksandr and Rittmeyer, Achim and Reck, Martin and Martinez-Marti, Alex and Kenmotsu, Hirotsugu and Chen, Yuh-Min and Chella, Antonio and Sugawara, Shunichi and Fu, Chenqi and Ballinger, Marcus and Deng, Yu and Srivastava, Minu K and Bennett, Elizabeth and Gitlitz, Barbara J and Wakelee, Heather A and IMpower010 Study Investigators, IMpower010 Study Investigators},
  title = {Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {21},
  pages = {2343--2349},
  doi = {10.1200/jco-24-01681}
}
Kostenlos starten →